Please input keywords

YH010 is a potentially first-in-class fully human PD-L1/IL-12 bi-specific antibody for the treatment of solid tumors. YH010 simultaneously activates the IL-12 signaling pathway while inhibiting PD-L1 binding to PD-1. YH010 also has the potential to further enhance the specific killing activity of T cells by tethering IL-12R positive T cells with PD-L1 positive tumor cells.